Neuronetics (NASDAQ:STIM) Major Shareholder Jorey Chernett Purchases 607,400 Shares of Stock

Neuronetics, Inc. (NASDAQ:STIM) major shareholder Jorey Chernett acquired 607,400 shares of the business’s stock in a transaction on Wednesday, March 18th. The stock was acquired at an average cost of $1.35 per share, with a total value of $819,990.00. Following the acquisition, the insider directly owned 8,123,804 shares in the company, valued at approximately $10,967,135.40. This trade represents a 8.08% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Jorey Chernett also recently made the following trade(s):

• On Thursday, March 19th, Jorey Chernett bought 450,000 shares of Neuronetics stock. The shares were acquired at an average cost of $1.33 per share, for a total transaction of $598,500.00.
• On Tuesday, March 17th, Jorey Chernett purchased 531,000 shares of Neuronetics stock. The stock was acquired at an average price of $1.16 per share, with a total value of $615,960.00.

Neuronetics Trading Down 4.3%

Shares of NASDAQ:STIM opened at $1.45 on Friday. The company has a market capitalization of $100.45 million, a P/E ratio of -2.46 and a beta of 0.87. Neuronetics, Inc. has a 1 year low of $0.80 and a 1 year high of $5.05. The company has a debt-to-equity ratio of 2.51, a current ratio of 2.02 and a quick ratio of 2.09. The business’s 50 day simple moving average is $1.60 and its 200 day simple moving average is $2.03.

Neuronetics (NASDAQ:STIM) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. The firm had revenue of $41.78 million for the quarter, compared to analyst estimates of $40.84 million. Neuronetics had a negative return on equity of 121.26% and a negative net margin of 26.15%. On average, research analysts anticipate that Neuronetics, Inc. will post -1.13 EPS for the current fiscal year.

Institutional Trading of Neuronetics

A number of hedge funds have recently added to or reduced their stakes in STIM. Goldman Sachs Group Inc. increased its holdings in shares of Neuronetics by 2,993.3% during the first quarter. Goldman Sachs Group Inc. now owns 630,393 shares of the company’s stock worth $2,320,000 after buying an additional 610,014 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Neuronetics by 172.3% during the 2nd quarter. Geode Capital Management LLC now owns 879,045 shares of the company’s stock valued at $3,068,000 after acquiring an additional 556,268 shares in the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Neuronetics during the 2nd quarter valued at $34,000. Intech Investment Management LLC bought a new stake in Neuronetics during the 2nd quarter worth $64,000. Finally, JPMorgan Chase & Co. grew its position in Neuronetics by 195,023.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 66,342 shares of the company’s stock worth $232,000 after acquiring an additional 66,308 shares during the last quarter. Institutional investors and hedge funds own 53.59% of the company’s stock.

Neuronetics News Roundup

Here are the key news stories impacting Neuronetics this week:

• Positive Sentiment: Major insider buying: Jorey Chernett (a major shareholder) increased his stake with multiple purchases over March 17–19 totaling roughly 1.59M shares across filings, boosting ownership and signaling insider confidence. SEC Form 4 filing Investing.com coverage
• Positive Sentiment: Q4 results modestly beat expectations: EPS of ($0.10) vs. (~$0.12) est. and revenue $41.8M vs. $40.8M expected — a near‑term operational positive but the company remains unprofitable. Earnings call transcript
• Neutral Sentiment: Mixed analyst and institutional profile: MarketBeat notes one Buy and one Sell rating, a consensus “Hold,” active institutional turnover, and wide variance in targets — underlines divergent views and liquidity sensitivity for this small‑cap stock. MarketBeat coverage
• Negative Sentiment: Price‑target reduction from Canaccord: Canaccord cut its target from $7 to $3 (still a Buy), narrowing perceived upside and likely weighing on sentiment despite the maintained rating. Benzinga report
• Negative Sentiment: Short‑term sell pressure / headline reaction: AAII and other outlets highlighted a multi‑percent intraday decline (around 5%), attributing it to the mix of analyst action, profit‑taking after recent moves, and the company’s continued negative margins and leverage. AAII article

Wall Street Analysts Forecast Growth

STIM has been the topic of a number of analyst reports. Canaccord Genuity Group reduced their price objective on shares of Neuronetics from $7.00 to $3.00 and set a “buy” rating on the stock in a research note on Thursday. Weiss Ratings restated a “sell (e+)” rating on shares of Neuronetics in a research report on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of Neuronetics from a “hold” rating to a “sell” rating in a research report on Saturday. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $3.00.

Neuronetics Company Profile

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.